The tumor–TME interaction based on the IHC expression pattern of PD-L1, PD-L2, and PD-1 in EC demonstrated that PD-1-PD-L1/2 immune signaling could be blocked in the tumor stroma. The gene discussed is PDCD1; the disease is neoplasm.